CCL22 and metastatic malignant neoplasm in the lymph nodes: The group with lower number of CCL22 (+) cells had 42.7% (88/206) lymph node metastasis, 55.8% (115/206) FIGO stage I to II, 38.3% (79/206) cases treated by surgery, and 11.2% (23/206) in death.